Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy.
暂无分享,去创建一个
Jinlei Bian | Zhiyu Li | Jinlei Bian | T. Weng | Tianwei Weng | Xiaqiu Qiu | Jubo Wang | Zhiyu Li | Jubo Wang | Xiaqiu Qiu
[1] J. Frère,et al. Discovery and preliminary SARs of keto-indoles as novel indoleamine 2,3-dioxygenase (IDO) inhibitors. , 2011, European journal of medicinal chemistry.
[2] U. Grohmann,et al. T cell apoptosis by tryptophan catabolism , 2002, Cell Death and Differentiation.
[3] M. Bower,et al. INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology , 2017, ACS medicinal chemistry letters.
[4] O. Takikawa,et al. Tryptophan pyrrole ring cleavage enzymes in placenta. , 2003, Advances in experimental medicine and biology.
[5] J. Arthur,et al. Biochemical characteristics and inhibitor selectivity of mouse indoleamine 2,3-dioxygenase-2 , 2010, Amino Acids.
[6] D. Ross,et al. Benzofuranquinones as inhibitors of indoleamine 2,3-dioxygenase (IDO). Synthesis and biological evaluation. , 2014, Organic & biomolecular chemistry.
[7] J. Drevet,et al. Quantitative and spatial differences in the expression of tryptophan-metabolizing enzymes in mouse epididymis , 2006, Cell and Tissue Research.
[8] Yingxia Li,et al. Identification and preliminary structure-activity relationships of 1-Indanone derivatives as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors. , 2017, Bioorganic & medicinal chemistry.
[9] K. Markides,et al. Quantitation of tryptophan, kynurenine and kynurenic acid in human plasma by capillary liquid chromatography-electrospray ionization tandem mass spectrometry. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[10] P. Sharma,et al. The future of immune checkpoint therapy , 2015, Science.
[11] Qian Wang,et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. , 2010, Blood.
[12] A. Venkateswarlu,et al. Novel indolo[2,1-b]quinazoline analogues as cytostatic agents: synthesis, biological evaluation and structure-activity relationship. , 2002, Bioorganic & medicinal chemistry letters.
[13] Charles J. Link,et al. Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. , 2013 .
[14] L. Jermiin,et al. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. , 2007, Gene.
[15] B. Clement. REDUCTION OF N-HYDROXYLATED COMPOUNDS: AMIDOXIMES (N-HYDROXYAMIDINES) AS PRO-DRUGS OF AMIDINES , 2002, Drug metabolism reviews.
[16] Tetsuya Kohno,et al. Crystal Structures and Structure-Activity Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors. , 2014, ACS medicinal chemistry letters.
[17] D. Ross,et al. Synthesis and Intracellular Redox Cycling of Natural Quinones and Their Analogues and Identification of Indoleamine-2,3-dioxygenase (IDO) as Potential Target for Anticancer Activity. , 2015, Angewandte Chemie.
[18] G. Prendergast,et al. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors , 2005, Expert opinion on therapeutic targets.
[19] M. Micallef,et al. Cell differentiation and apoptosis of monocytic and promyelocytic leukemia cells (U‐937 and HL‐60) by tryptanthrin, an active ingredient of Polygonum tinctorium Lour. , 2001, Pathology international.
[20] Ming-Rong Zhang,et al. Development of 1-N-11C-Methyl-l- and -d-Tryptophan for pharmacokinetic imaging of the immune checkpoint inhibitor 1-Methyl-Tryptophan , 2015, Scientific Reports.
[21] W. Wick,et al. Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors , 2015, Front. Immunol..
[22] G. Prendergast,et al. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. , 2007, Cancer research.
[23] Harikiran Lingabathula,et al. Novel substituted hydrazono indolo[2,1-b]quinazoline-6,12-dione analogues as cytostatic agents: Synthesis, crystal structure, biological evaluation and molecular docking studies. , 2016, Bioorganic & medicinal chemistry letters.
[24] J. McCarter,et al. Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors. , 2011, Biochimica et biophysica acta.
[25] J. Wolchok,et al. Immune modulation in cancer with antibodies. , 2014, Annual review of medicine.
[26] J. Wouters,et al. Indoleamine 2,3-dioxygenase inhibitory activity of derivatives of marine alkaloid tsitsikammamine A. , 2013, Bioorganic & medicinal chemistry letters.
[27] Olivier Michielin,et al. Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors. , 2015, Journal of medicinal chemistry.
[28] B. Eynde,et al. Tryptophan-Degrading Enzymes in Tumoral Immune Resistance , 2015, Front. Immunol..
[29] R. Gillies,et al. Synthesis of [(18) F] 4-amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide (IDO5L): a novel potential PET probe for imaging of IDO1 expression. , 2015, Journal of labelled compounds & radiopharmaceuticals.
[30] J. Renauld,et al. Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues , 2014, Cancer Immunology Research.
[31] Yi-Hui Peng,et al. Phenyl Benzenesulfonylhydrazides Exhibit Selective Indoleamine 2,3-Dioxygenase Inhibition with Potent in Vivo Pharmacodynamic Activity and Antitumor Efficacy. , 2016, Journal of medicinal chemistry.
[32] H. Ball,et al. Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway. , 2009, The international journal of biochemistry & cell biology.
[33] G. Prendergast,et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. , 2007, Cancer research.
[34] A. Luxen,et al. Fully automated radiosynthesis of N(1)-[(18)F]fluoroethyl-tryptophan and study of its biological activity as a new potential substrate for indoleamine 2,3-dioxygenase PET imaging. , 2016, Nuclear medicine and biology.
[35] M. Gompels,et al. Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients. , 1998, Clinical chemistry.
[36] C. Piccirillo,et al. Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives , 2011, Clinical Cancer Research.
[37] C. Boyd,et al. The role of l‐tryptophan transport in l‐tryptophan degradation by indoleamine 2,3‐dioxygenase in human placental explants , 2001, The Journal of physiology.
[38] W. Wick,et al. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. , 2012, Cancer research.
[39] L. Vécsei,et al. The kynurenine system and immunoregulation , 2012, Journal of Neural Transmission.
[40] Tingting Xu,et al. Structural insights into the binding mechanism of IDO1 with hydroxylamidine based inhibitor INCB14943. , 2017, Biochemical and biophysical research communications.
[41] D. Hibbs,et al. The first indoleamine-2,3-dioxygenase-1 (IDO1) inhibitors containing carborane. , 2014, Dalton transactions.
[42] Paolo Vicini,et al. Abstract 4863: PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors , 2016 .
[43] N. King,et al. Molecules in focus: indoleamine 2,3-dioxygenase. , 2007, The international journal of biochemistry & cell biology.
[44] Jennifer Couzin-Frankel,et al. Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.
[45] U. Grohmann,et al. The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor ζ-Chain and Induce a Regulatory Phenotype in Naive T Cells1 , 2006, The Journal of Immunology.
[46] G. Prendergast,et al. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR , 2012, Oncoimmunology.
[47] C. Uyttenhove,et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.
[48] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[49] Charles J. Link,et al. Abstract 1633: Novel specific- and dual- tryptophan-2,3-dioxygenase (TDO) and indoleamine-2,3-dioxygenase (IDO) inhibitors for tumor immunotherapy , 2014 .
[50] S. Selvan,et al. Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies. , 2016, Current cancer drug targets.
[51] J. Markert,et al. Oncolytic Virotherapy for the Treatment of Malignant Glioma , 2017, Neurotherapeutics.
[52] Judith M. LaLonde,et al. Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. , 2008, Journal of medicinal chemistry.
[53] S. Fallarini,et al. In silico-driven multicomponent synthesis of 4,5- and 1,5-disubstituted imidazoles as indoleamine 2,3-dioxygenase inhibitors , 2016 .
[54] M. Sono,et al. Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2,3-dioxygenase. 1. Norharman and 4-phenylimidazole binding to the enzyme as inhibitors and heme ligands. , 1989, Biochemistry.
[55] Takafumi Suzuki,et al. Synthesis and biological evaluation of novel tryptoline derivatives as indoleamine 2,3-dioxygenase (IDO) inhibitors. , 2013, Bioorganic & medicinal chemistry.
[56] D. Munn,et al. Indoleamine 2,3‐dioxygenase contributes to tumor cell evasion of T cell‐mediated rejection , 2002, International journal of cancer.
[57] D. Fuchs,et al. More rapid method for simultaneous measurement of tryptophan and kynurenine by HPLC. , 2002, Clinical chemistry.
[58] A. Macchiarulo,et al. Docking Studies and Molecular Dynamic Simulations Reveal Different Features of IDO1 Structure , 2016, Molecular informatics.
[59] A. Coluccia,et al. New Inhibitors of Indoleamine 2,3-Dioxygenase 1: Molecular Modeling Studies, Synthesis, and Biological Evaluation. , 2016, Journal of medicinal chemistry.
[60] Judith M. LaLonde,et al. Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. , 2008, Journal of medicinal chemistry.
[61] C. L. Costantino,et al. Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. , 2009, Journal of the American College of Surgeons.
[62] B. Palmer,et al. Discovery and characterisation of hydrazines as inhibitors of the immune suppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO1). , 2013, Bioorganic & medicinal chemistry.
[63] J. Jamie,et al. Natural Product-Inspired Pyranonaphthoquinone Inhibitors of Indoleamine 2,3-Dioxygenase-1 (IDO-1) , 2013 .
[64] G. Prendergast,et al. Marrying immunotherapy with chemotherapy: why say IDO? , 2005, Cancer research.
[65] Jian Li,et al. Successful treatment of refractory Sezary syndrome by anti-PD-1 antibody (nivolumab) , 2017, Annals of Hematology.
[66] H. Weinmann. Cancer Immunotherapy: Selected Targets and Small‐Molecule Modulators , 2016, ChemMedChem.
[67] P. Verhoest,et al. Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway. , 2015, Journal of medicinal chemistry.
[68] J. Fridman,et al. Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors , 2010, Molecular Cancer Therapeutics.
[69] G. Prendergast,et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy , 2005, Nature Medicine.
[70] L. Rendina,et al. Targeting key dioxygenases in tryptophan-kynurenine metabolism for immunomodulation and cancer chemotherapy. , 2015, Drug discovery today.
[71] K. Matsuno,et al. Identification of novel kynurenine production-inhibiting benzenesulfonamide derivatives in cancer cells. , 2012, Biochemical and biophysical research communications.
[72] Steven A. Rosenberg,et al. Raising the Bar: The Curative Potential of Human Cancer Immunotherapy , 2012, Science Translational Medicine.
[73] R. Frédérick,et al. Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008 – 2012) , 2013, Expert opinion on therapeutic patents.
[74] Qian Wang,et al. Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. , 2009, Journal of medicinal chemistry.
[75] J. Frère,et al. Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors. , 2011, Bioorganic & medicinal chemistry.
[76] H. Ball,et al. 1-L-methyltryptophan is a more effective inhibitor of vertebrate IDO2 enzymes than 1-D-methyltryptophan. , 2010, Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology.
[77] A. Tai,et al. Inhibition of hepatocyte growth factor induction in human dermal fibroblasts by tryptanthrin. , 2005, Biological & pharmaceutical bulletin.
[78] Takashi Otsuki,et al. Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[79] P. Sharma,et al. Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential , 2015, Cell.
[80] Su-Ying Wu,et al. Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1. , 2016, Journal of medicinal chemistry.
[81] B. Baban,et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. , 2004, The Journal of clinical investigation.
[82] A. Luxen,et al. N (1)-Fluoroalkyltryptophan Analogues: Synthesis and in vitro Study as Potential Substrates for Indoleamine 2,3-Dioxygenase. , 2015, ACS medicinal chemistry letters.
[83] Y. Chao,et al. Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors. , 2014, Bioorganic & medicinal chemistry letters.
[84] D. Schrenk,et al. Tryptanthrins: a novel class of agonists of the aryl hydrocarbon receptor. , 1997, Biochemical pharmacology.
[85] Shan Qian,et al. IDO as a drug target for cancer immunotherapy: recent developments in IDO inhibitors discovery , 2016 .
[86] M. Durcan,et al. Identification of Tryptophan 2,3‐Dioxygenase RNA in Rodent Brain , 1993, Journal of neurochemistry.
[87] M. Micallef,et al. Prevention of azoxymethane-induced intestinal tumors by a crude ethyl acetate-extract and tryptanthrin extracted from Polygonum tinctorium Lour. , 2001, Anticancer research.
[88] P. Darcy,et al. Clinical application of genetically modified T cells in cancer therapy , 2014, Clinical & translational immunology.
[89] R. Andersen,et al. Indoleamine 2,3-dioxygenase inhibitors isolated from the sponge Xestospongia vansoesti: structure elucidation, analogue synthesis, and biological activity. , 2014, Organic letters.
[90] S. Paul,et al. Nitrobenzofurazan derivatives of N'-hydroxyamidines as potent inhibitors of indoleamine-2,3-dioxygenase 1. , 2016, European journal of medicinal chemistry.
[91] Zhiyu Li,et al. Research progress of indoleamine 2,3-dioxygenase inhibitors. , 2015, Future medicinal chemistry.
[92] S. Fujii,et al. Induction of tryptophan 2,3-dioxygenase in the mouse endometrium during implantation. , 2000, Biochemical and biophysical research communications.
[93] B. Palmer,et al. Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions. , 2017, European journal of medicinal chemistry.
[94] Qing Yang,et al. Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice. , 2013, Journal of medicinal chemistry.
[95] M. Hemann,et al. A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy. , 2015, Journal of the American Chemical Society.
[96] C. L. Costantino,et al. Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival , 2009, Cell cycle.
[97] Enzyme kinetics and molecular evolution , 1989 .
[98] G. Prendergast,et al. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer , 2014, Cancer Immunology, Immunotherapy.